User:Mr. Ibrahem/Golimumab

Golimumab, sold under the brand name Simponi, is a medication used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. It is given by injection under the skin.

Common side effects include upper respiratory tract infection. Other side effects may include sepsis, pneumonia, reactivation of hepatitis B, heart failure, allergic reactions, vasculitis, and leukemia. Use in pregnancy and breastfeeding is of unclear safety. It is a monoclonal antibody which is attaches to and blocks tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule.

Golimumab was approved for medical use in the United States and Europe in 2009. It is on the World Health Organization's List of Essential Medicines as an alternative to adalimumab. In the United Kingdom 100 mg costs the NHS about £1,500 as of 2021. In the United States this amount costs about 6,300 USD.